Edwards Lifesciences (EW): New Buy Recommendation for This Healthcare Giant

By Ryan Adsit

In a report released today, Raj Denhoy from Jefferies maintained a Buy rating on Edwards Lifesciences (EWResearch Report), with a price target of $180. The company’s shares closed on Tuesday at $157.35.

According to TipRanks.com, Denhoy is a top 25 analyst with an average return of 19.1% and a 69.2% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Integra Lifesciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $166.85 average price target, implying a 6.0% upside from current levels. In a report issued on November 30, Cowen & Co. also assigned a Buy rating to the stock with a $190 price target.


See today’s analyst top recommended stocks >>

Based on Edwards Lifesciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $226 million. In comparison, last year the company had a net profit of $170 million.

Based on the recent corporate insider activity of 113 insiders, corporate insider sentiment is negative on the stock. Last month, Robert Sellers, the VP, Corp. Contr of EW sold 7,859 shares for a total of $1,203,631.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care.